OTX015: Phase IIa started

Oncoethix began an open-label, dose-escalation, European Phase IIa trial to evaluate once-daily oral OTX015 in about 51 patients. Oncoethix has exclusive, worldwide rights to OTX015 from Mitsubishi Ta...